Effectiveness of six international guidelines using FIB-4 and FibroScan for risk stratification of MASLD in type 2 diabetes

Hepatology

Effectiveness of a model of care based on Fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: results from an Italian prospective multicentre study

Am J Gastroenterol

Caviglia GP, Ferro A, D'Ambrosio R, Perbellini R, Lampertico P, Periti G, Valenti L, Ciccioli C, Pennisi G, Petta S, Brodosi L, Petroni ML, Marchignoli F, Pironi L, Sagripanti A, Argenziano ME, Svegliati-Baroni G, Rosso C, Barutta F, Armandi A, Gruden G, Bugianesi E

doi: 10.14309/ajg.0000000000003493

Hepatology

Effect of antidiabetic drug classes on the risk of liver-related events in individuals with T2D and MASLD

Clin Gastroenterol Hepatol

Shi Y, Kim SU, Cheuk-Fung Yip T, Tsochatzis E, Petta S, Nakajima A, Hagström H, Bugianesi E, Chan WK, Boursier J, George Goh BB, Sanyal AJ, Romero-Gomez M, Calleja JL, de Lédinghen V, Newsome PN, Fan JG, Lai M, Castéra L, Fournier C, Lee HW, Lai-Hung Wong G, Pennisi G, Yoneda M, Shang Y, Armandi A, de Saint-Loup M, Canivet CM, Kim-Jun Teh K, Asgharpour A, Gallego-Durán R, Llop E, Lara-Romero C, Sau-Wai Chan M, Mahgoub S, Lin H, Liu WY, Targher G, Byrne CD, Wai-Sun Wong V, Zheng MH, VCTE-Prognosis Study Group

doi: 10.1016/j.cgh.2025.06.001

Inflammatory Bowel Disease

Metformin Is Associated With Improved Inflammatory Bowel Disease Outcomes in Patients With Type 2 Diabetes Mellitus: A Propensity-Matched Cohort Study

Inflamm Bowel Dis

Petrov JC, Desai AA, Kochhar GS, Crosby SK, Kinnucan JA, Picco MF, Hashash JG, Farraye FA

doi: 10.1093/ibd/izae147

Further Publications

Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study

Lancet Gastroenterol Hepatol

Lindfors A, Strandberg R, Hagström H

doi: 10.1016/S2468-1253(24)00313-3

Hepatology

Phase 3 validation of PAaM for hepatocellular carcinoma risk stratification in cirrhosis

Gastroenterology

Fujiwara N, Lopez C, Marsh TL, Raman I, Marquez CA, Paul S, Mishra SK, Kubota N, Katz C, Kanzaki H, Gonzalez M, Quirk L, Deodhar S, Selvakumar P, Raj P, Parikh ND, Roberts LR, Schwartz ME, Nguyen MH, Befeler AS, Page-Lester S, Srivastava S, Feng Z, Reddy KR, Khaderi S, Asrani SK, Kanwal F, El-Serag HB, Marrero JA, Singal AG, Hoshida Y

doi: 10.1053/j.gastro.2024.10.035

Hepatology

High inherited risk predicts age-associated increases in fibrosis in patients with MASLD

J Hepatol

Díaz LA, Alazawi W, Agrawal S, Arab JP, Arrese M, Idalsoaga F, Barreyro FJ, Gadano A, Marciano S, Morales JM, Villela-Nogueira C, Leite N, Couto CA, Theodoro R, Joyner de Sousa Dias Monteiro M, Oliveira CP, Pessoa MG, Alvares-da-Silva MR, Madamba E, Bettencourt R, Richards LM, Majithia AR, Khera AV, Loomba R, Ajmera V

doi: 10.1016/j.jhep.2025.04.035

Irritable Bowel Syndrome (IBS) and Chronic Constipation

Optimizing Cost-Effective Care for Chronic Constipation in General Gastroenterology Using an Office-Based, Point-Of-Care Test (RED): Cost-Effectiveness and Cost-Minimization Analysis

Am J Gastroenterol

Shah ED, Chey WD

doi: 10.14309/ajg.0000000000002989

Hepatology

Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure

Hepatology

Semmler G, Alonso López S, Pons M, Lens S, Dajti E, Griemsmann M, Zanetto A, Burghart L, Hametner-Schreil S, Hartl L, Manzano M, Rodriguez-Tajes S, Zanaga P, Schwarz M, Gutierrez ML, Jachs M, Pocurull A, Polo B, Ecker D, Mateos B, Izquierdo S, Real Y, Balcar L, Carbonell-Asins JA, Gschwantler M, Russo FP, Azzaroli F, Maasoumy B, Reiberger T, Forns X, Genesca J, Bañares R, Mandorfer M

doi: 10.1097/HEP.0000000000001005

Inflammatory Bowel Disease

Developing IBD Outcome Effect Size Thresholds to Inform Research, Guidelines, and Clinical Decisions

Inflamm Bowel Dis

Gordon M, Shaban N, Sinopoulou V, Vuyyuru S, Radford S, Magro F, Armuzzi A, Peyrin-Biroulet L, Jairath V, Moran G

doi: 10.1093/ibd/izaf085

Related content

Effectiveness of a model of care based on Fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: results from an Italian prospective multicentre study

Effect of antidiabetic drug classes on the risk of liver-related events in individuals with T2D and MASLD

Metformin Is Associated With Improved Inflammatory Bowel Disease Outcomes in Patients With Type 2 Diabetes Mellitus: A Propensity-Matched Cohort Study

Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study

Phase 3 validation of PAaM for hepatocellular carcinoma risk stratification in cirrhosis

High inherited risk predicts age-associated increases in fibrosis in patients with MASLD

Optimizing Cost-Effective Care for Chronic Constipation in General Gastroenterology Using an Office-Based, Point-Of-Care Test (RED): Cost-Effectiveness and Cost-Minimization Analysis

Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure

Developing IBD Outcome Effect Size Thresholds to Inform Research, Guidelines, and Clinical Decisions